Helus Pharma, formerly known as Cybin, saw a 7.53% share price increase to $4.36 on Friday, though the stock has lost about 51% of its value year-to-date. This uptick was linked to a broader biotech market rally and the recent acquisition of Transcend Therapeutics by Otsuka Pharmaceutical, which adds credibility to the psychedelic-therapeutics sector where Helus is focused. The company’s lead asset, HLP003, is in Phase 3 for major depressive disorder and has received FDA Breakthrough Therapy designation. Despite regulatory momentum and potential clinical advancements, concerns remain due to high volatility and significant stock declines, with upcoming data releases expected to be pivotal for investor confidence.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.ad-hoc-news.de/boerse/news/ueberblick/helus-pharma-a-biotech-tightrope-between-regulatory-tailwinds-and-market/69530880
